Heart Disease News and Research

Latest Heart Disease News and Research

New drug for type 2 diabetes, Effect of insulin on bones

In a groundbreaking finding, a new medicine Galvus (vildagliptin) has been created for people with type 2 diabetes that would lower blood glucose levels without the side effects of other medications.

26 Jul 2010

East Tennessee Children's Hospital selects ProVation Order Sets, powered by UpToDate Decision Support

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that East Tennessee Children's Hospital has selected ProVation® Order Sets, powered by UpToDate® Decision Support, to automate the creation, deployment and maintenance of order sets.

26 Jul 2010

Today's OpEds: Health reform and long-term care; Health care incentives; Reasons for optimism or repeal and replace?

Our system of long-term care does not provide adequate or coordinated human services and medical treatment for our growing aging population. … Thanks to a provision of the new health care law known as the Community Living Assistance Services and Supports program, tomorrow's continuum of care does not have to be so unforgiving. For the first time, a voluntary public insurance program will be available to help adults and families pay for long-term care services (Bruce Chernof, 7/23).

26 Jul 2010

KIKA Clinical Solutions reports 47% increase in service bookings during first-half of 2010

KIKA™ Clinical Solutions is on track for unprecedented 2010 growth. KIKA is the leading provider of advanced EDC solutions for Clinical Asset Management™ for the pharmaceutical, biotechnology and medical device markets.

26 Jul 2010

Calibra Medical's Finesse insulin patch-pen receives FDA clearance for use with Novo Nordisk's Novolog

Calibra Medical announced today it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk's Novolog® rapid acting insulin. Combining the mealtime therapy-adherence benefits of insulin pumps with the simplicity and affordability of syringes and pens, Calibra's novel bolus-only patch-pen is a small, adhesively attached, flat device that can be operated discretely through clothing to deliver mealtime, snack time, and correction bolus insulin in seconds.

26 Jul 2010

New guidelines for care of heart transplant recipients from ISHLT

Since the dawn of heart transplantation in the 1960s, medical care of heart transplant recipients has varied from center to center and been guided by the experience of individual clinicians. The International Society for Heart and Lung Transplantation (ISHLT) has made an unprecedented commitment by convening experts in all areas of heart transplantation to develop practice guidelines for the care of heart transplant recipients.

26 Jul 2010

ESC concerned over interpretation of JUPITER sub-analysis trial results about HDL cholesterol

The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet, could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein (HDL) cholesterol. Caution, the ESC experts advise, should be displayed in the interpretation of the results.

26 Jul 2010

Methodist surgical team completes first phase training to implant new total artificial heart

A 13-member surgical team from the Methodist DeBakey Heart & Vascular Center completed the first phase of training to implant a new total artificial heart designed to completely replace the heart's function while the patient waits for a heart transplant. Methodist will be the first hospital in Texas to offer this total heart replacement.

26 Jul 2010

Cerenis, Novasep awarded French Government funding for development of CER-001 HDL mimetic

Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep (Novasep), a leading supplier of manufacturing solutions to the life sciences industries, announce today that they have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic.

26 Jul 2010

Boehringer Ingelheim announces European CHMP Positive Opinion for TWYNSTA

Boehringer Ingelheim announced today that the European Committee for Medicinal Products for Human Use (CHMP) adopted a Positive Opinion for the approval of TWYNSTA®. It will be indicated in adults whose blood pressure is not adequately controlled on amlodipine and is also indicated as replacement therapy in adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of TWYNSTA containing the same component doses.

26 Jul 2010

Cerenis Therapeutics closes first round of series C, raises €40 million

Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company specializing in the research and development of novel therapies based on the metabolism of HDL (the "good" cholesterol) to treat cardiovascular and other metabolic diseases, announced today it has raised €40 million in the first close of its series C financing. In this round €20 million came from the Fund for Strategic Investment (FSI) with an additional €20 million coming from the existing investors: Sofinnova Partners, HealthCap, Alta Partners and TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.

26 Jul 2010

Report on neuropsychological effects after surgery for acyanotic heart defects

School-aged children who undergo cardiopulmonary bypass (CPB) during surgery for less complicated congenital heart defects do not appear to suffer any impairments in neurocognitive abilities, such as intelligence, memory, motor skills and behavior.

26 Jul 2010

CUTCO Cutlery donates over a half million dollars to support Go Red For Women movement

In just over three years, CUTCO Cutlery has donated over a half million dollars to support the American Heart Association's Go Red For Women movement.

26 Jul 2010

Neu5Gc in drugs provokes strong immune response

Researchers at the University of California, San Diego School of Medicine have discovered that a kind of sugar molecule common to chimpanzees, gorillas and other mammals but not found in humans provokes a strong immune response in some people, likely worsening conditions in which chronic inflammation is a major issue.

26 Jul 2010

HTG patients face increased risk for heart disease, stroke: Study

It can make blood look like cream of tomato soup. Patients with high levels of triglycerides in their blood, a disease called hypertriglyceridemia face an increased risk for heart disease and stroke. HTG affects one in 20 people in North America and is also associated with obesity, diabetes and pancreatitis. Most people now understand the importance of LDL, the bad cholesterol and HDL, the good cholesterol, to their overall health.

26 Jul 2010

Inhibiting fatty acid synthase can reduce atherosclerosis: Study

Scientists at Washington University School of Medicine in St. Louis have found a way to significantly reduce atherosclerosis in mice that does not involve lowering cholesterol levels or eliminating other obesity-related problems.

26 Jul 2010

Ohio sets up high risk pool; Four drug companies come under scrutiny for payments to Pittsburgh doctors, nurses

"Ohioans with pre-existing health conditions, such as cancer or diabetes, can apply for coverage under a new high-risk insurance pool beginning Aug. 1." Qualifications include evidence of a pre-existing condition, proof of Ohio residency and U.S. citizenship, state of being uninsured for six months prior to the date of applying for coverage and being "ineligible for coverage under the Medicare program, the Ohio Medical Assistance Program, the Ohio Children's Health Insurance Program, or an employer-sponsored group health plan, unless subject to a mandatory initial waiting period" (7/22).

26 Jul 2010

First generic version of Lovenox receives FDA approval for DVT

The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis, a potentially deadly blood clotting condition.

23 Jul 2010

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.

23 Jul 2010

CRF Health collects prestigious IPA Best of Health Awards

CRF Health garnered nine awards recently in the Business-to-Business categories of the Institute of Practitioners in Advertising Best of Health Awards, for their bold, new communications aimed at healthcare professionals involved in clinical trials. The awards were collected by their creative agency behind the campaign, Langland, at the awards night in London.

23 Jul 2010

Heart Disease News and Research

Latest Heart Disease News and Research

New drug for type 2 diabetes, Effect of insulin on bones

East Tennessee Children's Hospital selects ProVation Order Sets, powered by UpToDate Decision Support

Today's OpEds: Health reform and long-term care; Health care incentives; Reasons for optimism or repeal and replace?

KIKA Clinical Solutions reports 47% increase in service bookings during first-half of 2010

Calibra Medical's Finesse insulin patch-pen receives FDA clearance for use with Novo Nordisk's Novolog

New guidelines for care of heart transplant recipients from ISHLT

ESC concerned over interpretation of JUPITER sub-analysis trial results about HDL cholesterol

Methodist surgical team completes first phase training to implant new total artificial heart

Cerenis, Novasep awarded French Government funding for development of CER-001 HDL mimetic

Boehringer Ingelheim announces European CHMP Positive Opinion for TWYNSTA

Cerenis Therapeutics closes first round of series C, raises €40 million

Report on neuropsychological effects after surgery for acyanotic heart defects

CUTCO Cutlery donates over a half million dollars to support Go Red For Women movement

Neu5Gc in drugs provokes strong immune response

HTG patients face increased risk for heart disease, stroke: Study

Inhibiting fatty acid synthase can reduce atherosclerosis: Study

Ohio sets up high risk pool; Four drug companies come under scrutiny for payments to Pittsburgh doctors, nurses

First generic version of Lovenox receives FDA approval for DVT

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

CRF Health collects prestigious IPA Best of Health Awards

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Heart Disease News and Research

Latest Heart Disease News and Research

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in